

# Annual Report and Accounts

2016-17



---

**We are the only UK charity dedicated to improving the lives of people with Scleroderma and Raynaud's phenomenon.**

---

**We are here to improve awareness and understanding of these conditions, to support those affected, and ultimately, to find a cure.**

**We currently support over 162,000 people each year. Our aim is to reach out to every single person who has a Scleroderma or Raynaud's diagnosis, providing them with the information and support they need.**

**By creating connections between people with the conditions and professionals, we have built a motivated community that shares knowledge and support, works in partnership on research projects, and speaks up about Scleroderma and Raynaud's.**

**We have a stronger voice together.**




**"I am honoured to be President of Scleroderma & Raynaud's UK. Our charity is a unique collective source of experience, providing access to support and well-researched information, often not to be found elsewhere."**

**Dame Carol Black**  
SRUK President


# Contents

## Overview



Message from Chair and Chief Executive	4
Our Organisation	5
Highlights of the Year	6

## Trustees report: Strategic Report




Support	8
Research	10
Awareness	12
Future direction	14
Income generation	16
Financial review	18
Principal risks and uncertainties	19
Legal structure and governance	20
Statement of Trustees' responsibilities	21
<b>Independent auditor's report</b>	<b>22</b>

## Financial Statements



Consolidated statement of financial activities	23
Charity statement of financial activities	24
Consolidated and charity balance sheets	25
Notes to the consolidated financial statements	26
Legal and administrative details	43



---

# Message from our Chair and Chief Executive

SRUK's first year of operation was extremely busy and eventful and we are pleased to report that the transition phase to create one organisation is now complete. We would like to thank each and every one of you for your support in helping to establish SRUK.

---

SRUK will build on the strong legacy we have inherited from the Raynaud's & Scleroderma Association and Scleroderma Society. Both charities understood the importance of research and that investment would lead to a better understanding of the conditions, effective treatments and new treatment pathways.

We work in partnership with people affected by Scleroderma and Raynaud's to inform, develop and deliver our work, ensuring our community has a strong voice and plays an integral part in the development of SRUK's services.

We're now looking forward and planning our work over the next five years. You told us that there needs to be far greater awareness of the conditions; improvements in time to diagnosis with timely and effective interventions and an increase in funding for research.

Over the next five years we want to significantly increase our investment in research. Our scientists and researchers have achieved so much and continue to be at the forefront of pioneering developments. Right now, there are exciting trials taking place that may lead to better or new treatments becoming available. We want to build on the breakthroughs of recent years and with your support continue to help our researchers find the answers we need.


It's only by working together that we will achieve the growth needed to bring about real transformation and change. By uniting as a community, we really can make a difference to the future of everyone affected by Scleroderma and Raynaud's.



**Professor Jeremy Pearson**  
Chair



**Sue Farrington**  
Chief Executive



# Our Organisation

## Joining forces

SRUK launched on 31st March 2016 and is a new charity formed by the merger of the Raynaud's & Scleroderma Association (RSA) and the Scleroderma Society.

By bringing the support, expertise and passion of the two organisations together, we have a strong new organisation focused on supporting people with Scleroderma and Raynaud's, funding and campaigning for research into the conditions and dedicated to building better understanding and treatment for everyone affected by them.

## Our vision

**Our vision is a world where no-one has their life limited by Scleroderma and Raynaud's.**

## Our mission

**Our mission is to improve the lives of everyone affected by Scleroderma and Raynaud's.**

We do this by investing in research, improving awareness and understanding of the conditions and providing information and support to all those affected.

## Our values

**Our brand development work identified four core values, which inform the way we work, behave and do business.**



**Collaborative**  
in the way we work



**Driven**  
to see real change



**Trusted** because we are open and honest about the way we work



**Compassionate** because we always put the person first

Scleroderma is a rare, chronic auto-immune condition affecting connective tissue and blood vessels. In the UK there are around 12,000 people diagnosed with the condition. The cause is unknown, and prognosis is poor, often leading to multi-organ dysfunction. Some forms of the disease are life-threatening; all forms impact on a person's quality of life.

Raynaud's is a more common condition, estimated to affect up to 10 million people in the UK. It is a vascular condition affecting the blood vessels in the extremities of the body, commonly fingers and toes, but all extremities can be involved. With Primary Raynaud's symptoms are usually mild and manageable. The causes of the condition are unknown, but Raynaud's attacks can be brought on by a change in ambient temperature or stress.

The affected extremities turn white, feel cold and numb and often extremely painful, making everyday tasks difficult. Raynauds can develop at any age, while relatively rare in children, it can be common in teenagers.


Secondary Raynaud's, which is more serious and can lead to ulceration and calcification, is associated with the presence of an auto-immune connective tissue disease and can often be the first indication for the disease. Up to 97% of patients diagnosed with Scleroderma have secondary Raynaud's.

## Strategic report

During 2015-16 we identified a number of strategic priorities to take SRUK through its first and transitional year.

### Strategic Priorities:

- Provide support for people with Scleroderma and Raynaud's
- Establish a strategic approach to funding research
- Increase awareness of Scleroderma and Raynaud's
- Establish a clear direction of travel for SRUK
- Protect, grow and diversify income



# Highlights



## 1st Jun

Featured as Unite/CPHVA's charity of the month - educating over 100,000 community health practitioners.

## 8th Jun

Attended EULAR congress, promoting SRUK and connecting with other European patient organisations and clinicians.

## 10th Jun

Launched our first public facing awareness campaign to increase awareness and understanding of Scleroderma and Raynaud's. We reached over 38 million people.

## 1st Jul

First SRUK research projects awarded funding, to improve knowledge and advance treatment for Scleroderma and Raynaud's.

## 2nd Jul

Our first family day, working alongside paediatric specialists provided a day of education and support to families with children affected by these conditions.

Mar 2016	Apr 2016	Jun 2016	Jul 2016
<p><b>31st Mar</b></p> <p>Scleroderma &amp; Raynaud's UK went live and the new website launched.</p>	<p><b>26th Apr</b></p> <p>Met key clinicians and researchers at BSR conference Glasgow and held first talks about establishing an alliance to improve care and services for rare autoimmune conditions.</p>	<p><b>29th Jun</b></p> <p>Joined the global awareness campaign, World Scleroderma Day. Our social media campaign #KnowRaynauds, explaining the link between Scleroderma and Raynaud's, reached 108,000 people.</p>	<p><b>31st Jul</b></p> <p>We joined forces with the British Society for Rheumatology (BSR), Lupus UK and Vasculitis UK to establish the Rare Autoimmune Rheumatic Disease Alliance.</p>



2nd Jul | First Family Day



14<sup>th</sup> Jan | Research Priorities

3<sup>rd</sup> Sept

Our first annual conference brought the community together to hear from leading specialists on the latest advancements in treatment and research.

10<sup>th</sup> Nov

Retained The Information Standard accreditation confirming our commitment to producing clear, accurate, evidence based information that you can rely on and trust.

14<sup>th</sup> Jan

Shaped our research strategy through community involvement.  
247 people told us what their research priorities were to direct our future investment in research.

1<sup>st</sup> Feb

We supported 4,615 people during Raynaud's Awareness Month to identify if they could have Raynaud's through the launch of our first online test.

Sep  
2016

Nov  
2016

Jan  
2017

Feb  
2017

Mar  
2017




3<sup>rd</sup> Sep | First Annual Conference

28<sup>th</sup> Feb

Our #raiseyourhands campaign increased awareness and understanding of Raynaud's.  
We reached over 45 million people through broadcast media and 169,000 people on social media.

20<sup>th</sup> Mar

SRUK's first five-year strategy developed (2017 - 2021) to ensure we are focussed on achieving what you have told us you want.



# Provide support for people with Scleroderma and Raynaud's

In January 2016, when we surveyed our community about their needs, 70% of respondents said managing their symptoms or conditions was their biggest challenge.

At SRUK we support those with Scleroderma and Raynaud's through the provision of evidence based, up to date, quality information to help people better manage their condition and make decisions about their care.

We want people with Scleroderma and Raynaud's to see us as a trusted source of information, whether in print, online, phone or at events. We continue to be a certified member of The Information Standard. This quality mark shows our information is clear, accurate, impartial, evidence-based and up to date.

SRUK provides a volunteer led helpline, offering support 365 days a year. The helpline is accredited to the Helplines Standard, a nationally recognised quality standard from the Helplines Partnership, which shows that the helpline follows best practice and meets the needs of people affected by Scleroderma and Raynaud's.

Events provide an opportunity for people to hear first-hand from renowned experts as well as the chance to meet, share stories and create support networks with other people affected by these conditions.

In July 2016, SRUK ran a Family Day in Birmingham, bringing together children, young people and their families and in September we held our first Annual Conference for the wider community.

“

Thank you again for arranging the family day, more so because my daughter has had a really tough time this last few years with her Scleroderma, and coming to the family day she was able to meet someone that is affected in a similar way that she is.

That has helped her a lot knowing she is not on her own.

Both the girls have exchanged numbers and have been chatting every day since, this wouldn't have happened without the SRUK family day.

Lisa

”



**15,332**

fact sheet downloads from our website [www.sruk.co.uk](http://www.sruk.co.uk)



**78%**

of delegates said their **confidence to self-manage had increased**



**1,838**

calls taken by our helpline and **over 103 hours** of support given to callers



**100%**

rated our events good to excellent - **93% rated very good to excellent**



“

When I found out about the charity it was a relief to know you are not the only one. By attending conferences and open days I don't feel I am alone and there is help and support available.

”

Zaida



**121**

members of the community attended the **First Annual Conference**




**Monthly Web Chats** took place from **January onwards**

to give specialist advice on 'living well with the conditions'



Our website, [www.sruk.co.uk](http://www.sruk.co.uk) had **over 511,000 unique visitors** in 2016/17

In February (Raynaud's Awareness Month) **4,615 people** took our **online Raynaud's test**



# Establish a strategic approach to funding research

Supporting research is one of the key aims of SRUK. We want to continue to fund world class research. We are driven to make real progress towards more effective treatments and a cure. We want to invest in innovative research projects at the forefront of the field.

To do this we need a clear understanding of the areas where our funding can have the greatest impact and to know which issues are of most importance to people with Raynaud's and Scleroderma.

During the year we prepared to submit our application to join the Association of Medical Research Charities (AMRC). This involved reviewing our grant processes, establishing a Research Sub-Committee and engaging our community in an exercise to prioritise the research topics of most importance.

## The top priorities are:

New and safer treatments

Detection of progression, complications and response to treatment

Improved and earlier detection and diagnosis

Causes of Scleroderma and Raynaud's phenomenon

Education of healthcare professionals

SRUK's research strategy will build on these topics and will help inform how the charity can best focus its resources for greatest patient benefit.

Our application to the AMRC was successful and SRUK become a member in May 2017. Membership of the AMRC is the hallmark of quality research funding and will give another level of reassurance to our donors.

## In 2016/17

### 18 active grants

#### New grants awarded

**£145,240**

#### Ongoing grants paid

**£115,825**

### 4 new grants awarded

#### Dr Emma Derrett-Smith (UCL):

"Molecular pathway analysis of keloidal morphea in systemic sclerosis"

#### Dr Alan Holmes et al (UCL):

"The role of Endothelial-to-Mesenchymal Transition in Scleroderma calcinosis"

#### Dr Clare Pain (Liverpool, Alder Hay):

"Assessing inflammation in childhood Scleroderma: comparison of imaging and skin examination"

#### Dr John Pauling et al (University of Bath):

"An Epidemiological Study of Systemic Sclerosis and its association with Cancer in the UK using the Clinical Practice Research Datalink (CPRD)"


A woman with dark hair tied back, wearing a white lab coat over a colorful patterned top and blue gloves, is looking down at a piece of equipment in a laboratory. In the background, there are shelves with various colored binders (red, black, blue) and a white wall with some papers.

“

The grant from SRUK has allowed us to show that cardiac magnetic resonance imaging (CMRI) can effectively identify patients at risk of heart involvement. The results will be used to secure support for a larger study, so we can introduce these improved methods of monitoring to real-world practice, improving patient outcomes and reducing sudden death.

Prof. Maya Buch

”



---

# Increase awareness of Scleroderma and Raynaud's

In a ComRes poll of 2,000 people, conducted in 2016, only 4% knew the symptoms of Raynaud's and this fell to 1% for Scleroderma.

---

Far too few people know about the conditions of Scleroderma and Raynaud's and this has serious and life-threatening consequences for thousands of people. Our research shows 67% of people believe Raynaud's affects only one person in 5,000 or even less, when the actual figure is 1 in 6.

This lack of awareness and understanding across public and professionals has led to poor support and treatment of Raynaud's and delayed diagnosis of Scleroderma.

The condition of Raynaud's is poorly understood, it is not treated seriously by many professionals and consequently we do not know exactly how many people are affected or how severely it affects people.

Raynaud's is to date the only known clinical manifestation considered to be a risk factor for developing Systemic Sclerosis or Scleroderma.

As a result, many people are going undiagnosed with severe Raynaud's and Scleroderma. This has serious, life threatening consequences for people with Scleroderma.

## **In 2016-17 we:**

Developed and ran 2 awareness raising campaigns in June '15 and Feb '16

---

Increased reach through targeted social media campaigns

---

Collaborated with external agencies to raise profile and awareness





Our first campaign for **World Scleroderma Day, #KnowRaynauds**, explaining the link between Scleroderma and Raynaud's reached

**108,000** people on **social media**



**8,090**

Facebook likes, that's an **increase of 22%**



Our **e-news** community grew by **86% to**

**5,672**

Our **Twitter** community grew by **140% to**

**1,969**



Our **#raiseyourhands** campaign engaged

**4**  
Online news sites

**3**  
National papers

**4**  
Local radio stations

**1**  
Welsh TV programme



**538,610**

people reached **on Twitter**

**800,365**

people reached **on Facebook**



Our **#raiseyourhands** campaign, increased awareness and understanding of Raynaud's, reaching over

**45 million people + 169,000**

people **on social media**

We worked with



to educate over

**100,000**

health visitors on signs and symptoms of Scleroderma and Raynaud's

“

Awareness is vital. I knew I had Raynaud's but when I started to experience pain when breastfeeding I didn't even think that it could be due to my condition. It was only when I started searching my symptoms I found information about Raynaud's in the nipples. As I used to be a hospital doctor I have been working with SRUK to educate frontline staff.

Caroline

”



# Establish a clear direction of travel for SRUK

During 2016-17 we developed a new five-year strategy for 2017-2021. This was based on extensive engagement with people with Scleroderma and Raynaud's, clinicians, researchers, staff and trustees, to gain insight into the key issues and challenges faced by the community and to understand what they wanted SRUK to achieve.

These findings were used to inform the development of an organisational Theory of Change for SRUK, which identified the key outcomes of importance for people affected by Scleroderma and Raynauds.

The outcomes fell into four key areas which helped define our strategic aims.

## Our strategic aims - 2017-2021

### 1 Awareness

Increase awareness of Scleroderma and Raynaud's with the public and health professionals.

### 2 Empowerment

Enable more people with Scleroderma and Raynaud's to manage their conditions through access to high quality information, support and guidance.

### 3 Healthcare

Ensure all people with Scleroderma and Raynaud's, across the UK have access to high quality, integrated health and social care services, which are responsive to their needs, and recognise them as equal partners in their care.

### 4 Research

Ensure that research funded by SRUK translates into better prevention, diagnosis and treatment outcomes.

“

Scleroderma is a terrible condition and it is reassuring to know that SRUK exists. I have supported SRUK for many years and will continue to do so, until everyone understands these conditions and a cure is found.

”

James Carver  
MEP

over **30%** said the biggest challenge was explaining their condition

**70%** of people on a daily basis said managing their symptoms and condition was the biggest challenge

## Our goals

A cure for Scleroderma and Raynauds is found


---

The impact of Scleroderma and Raynaud's on people's lives is minimised

---



## Our strategy



## Our ambition

### #1 Awareness

Increase awareness and understanding

---

### #2 Empowerment

Improve information and support

---

### #3 Healthcare

Enable early and accurate diagnosis  
Ensure equitable access to treatment and care

---

### #4 Research

New and more effective treatments  
Better understanding of causes and mechanisms





---

# Protect, grow and diversify Income

All of our work to increase awareness, empower patients, improve healthcare and expand our research programme depends entirely on the generosity of our supporters.

---

Through your donations, local collections, marathon running, work place fundraisers and the support of companies and grant giving trusts we are supporting over 162,000 people to live better every year.

In order to achieve our vision we must increase our funding. By 2020 we aim to be achieving an annual charity income of over £600,000 (excluding trading).

Areas that provide a significant contribution to our work are; our event and community fundraisers, supporters who leave a legacy to SRUK and those who donate in memory of a loved one.

## Legacies

Over half of our life-changing research is funded through gifts left to us in Wills and this year many of our dedicated supporters have remembered SRUK in this special way. Close to £278,000 was left to SRUK in 2016-17 to take us another step closer to finding a cure.

Every year we rely on these donations to fund our leading research programme. At SRUK, we believe that research has the power to transform the lives of everyone affected by Scleroderma and Raynaud's and with the generosity of our supporters we can ensure this vital work continues.

## Event and community fundraising

Each year hundreds of fundraisers join the fight against Scleroderma and Raynaud's. From joining Team SRUK at a challenge event to holding a bake sale, the dedication of our fundraisers to raise money and much needed awareness for SRUK is astounding.

During 2016-17 we have invested in our event programme to give our supporters even more ways in which to support the charity.

## In memory

Our community holds a very special place in our heart and many friends and family remember their loved ones each year through supporting SRUK. Donating in memory is a wonderful way to honour and remember, share happy memories and help other families facing the challenges Scleroderma and Raynaud's brings.


“

I was diagnosed with linear scleroderma when I was 8. The condition has shortened my left leg and damaged my muscle and nerves. Over the years SRUK has done so much for me and I know they rely on fundraising so I wanted to give something back.

In the summer I cycled from London to Paris, 350 miles over 3 days, which was an incredible challenge and such an achievement, the memories will stay with me forever.

Connor

”



“

Over the years SRUK has done so much for me... I wanted to give something back.

Connor

”



Supporters donated

over **£41,000**

in memory of their loved ones, helping other families affected by these conditions



over **£123,000**

given by donors to support our life changing work



over **£81,000**

raised by fundraisers for our support services, awareness raising and research



---

# Financial review

This report covers the period from 1 April 2016 to 31 March 2017.

---

## Overview

2016-17 was the first full year of operation for SRUK, as the newly merged charity. A major focus for the new charity is to improve impact and extend reach for people affected by Scleroderma and Raynaud's. To achieve growth, we must increase and diversify our fundraising and have a step change in our impact, effectiveness and efficiency. Making headway with this work has required us to take a longer-term approach in our financial planning with investment in a number of key areas. The charity's financial position in 2016-17 is reflective of this ambition.

Investment has been made in our fundraising capacity, but the full returns will take two to three years to mature. Our expenditure in 2016-17 reflects this strategic decision to invest in developing the engagement and development work of the charity including the appointment of a dedicated fundraiser.

Overall 2016-17 has been a year of transition and consolidation for the new charity following the merger, with some one-off costs related to the implementation of changes brought about by the merger.

## How we raised our money

In 2016-17 SRUK saw a total income of over £599,000, which represents an increase on the combined income received in the previous year. The key income streams for the charity comprise: Membership; Donations, Legacies, Trading and Fundraising Activities.

We received close to £246,000 in donations over the year showing a small decrease against the combined donations of the previous charities. However, we received a significant increase in legacy income compared to 2015-16, with close to £278,000 in 2016-17. As legacy income is unpredictable and subject to variation, the charity intends to focus on diversifying and increasing its other income streams.

The trading subsidiary of the charity brought in an income of over £56,000. This represents a reduction in income from 2015-16. This is due to the transition work on the shop following the merger, when the shop was moved to a new website.

## How we spent our money

During 2016-17 our total expenditure came to just over £758,000.

This expenditure included over £145,000 spent on Research Grants with a total of four new grants being awarded. We also invested in the development of a range of services:

Provision of information and support across all channels – print, online, phone and events. This included the development of the website and online platforms

---

Raising awareness of Scleroderma and Raynaud's with health care professionals and public

---

Establishing our campaigning and advocacy work through partnerships and alliances

---

Developing our infrastructure to ensure our organisation is efficient, effective and complies with all legal and regulatory requirements

## Balance sheet

As at 31 March 2017, total cash, deposits and investments stood at over £1,562,000.

## Reserves policy

The Trustee Board has specified a reserves policy which ensures that SRUK has sufficient funds to meet the cost of its day to day activities and is able to cope with the financial impact of unforeseen events. In addition, where possible funds should be set aside to meet future planned expenditure. These reserves are known as the operating reserve.

SRUK will hold sufficient financial reserves to ensure it can continue to operate in the event of unforeseen and potentially financially damaging circumstances arising.

The Board agreed that this amount should be equivalent to a minimum of six months' operating expenditure, which would amount to operating reserves of close to £307,000 in the current year as against the current free reserves of the group at £939,460 and charity at £946,447. The free reserves exclude any tangible assets.

### Investment policy

Rathbones Investment Management Limited became SRUK's investment manager in November 2016 following a transfer of the charity investment from M&G Investments. SRUK placed a portion of its assets (£500,000) into the Rathbones account to best maximise its financial return. Over this partial year the value of these investments increased to over £512,000.

As per SRUK's investment policy an investment manager at Rathbones was assigned to manage the investments of the charity. The investment manager reports on a quarterly basis on the performance of the investments under management. These reports are incorporated into the quarterly management accounts and the year-end accounts of the charity and reviewed by the Trustees at the quarterly board meetings.

The Board of Trustees carries out an annual review of the investment principles under which the managers operate.

### Grants policy

SRUK has adopted a new grants policy in which grants are accounted for fully in the year they are awarded in accordance with SORP 2015 requirements. They are therefore treated as liabilities in the accounts in the year they are awarded.

### Trading subsidiary

Over 2016-17 SRUK's trading subsidiary brought in over £56,000 of income and had expenditure of close to £47,000. Close to £11,000 of staff costs were paid back to the charity for the running of the shop, bringing total expenditure to over £57,000.

We have invested in improving the technical and online capability of the shop as well as its operational efficiency, reducing staff costs. The trading subsidiary is forecast to deliver a return to profit within the next two trading years.

### Going concern

After making appropriate enquiries, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. For this reason they continue to adopt the going concern basis in preparing the financial statements.

### Principal risks and uncertainties

SRUK is committed to effective risk management as an integral part of ensuring good corporate governance. Informed risk-taking helps to improve performance, manage our threats and opportunities and to create an environment of 'no surprises'. This will enable us to get the right balance between innovation and change.

As a new charity, we are reviewing and strengthening our risk management processes, to enable us to conclude whether major risks have been identified and reviewed.

#### Key principal risks identified include the need for:

- Clear strategic direction
- Sufficient financial resources

To help mitigate these risks, SRUK has implemented various initiatives, including the development of a five-year strategy, based on key outcomes from the organisation's Theory of Change developed in May 2016.

SRUK has implemented an annual financial budget and operational plan aimed at managing financial risks and progressing the strategic plan. These are monitored on a quarterly basis by the Board.

A fundraising strategy outlines how SRUK will raise the money to meet its strategic goals.

SRUK has opted for an audit, despite falling below the minimum requirement threshold, to ensure SRUK's processes and systems are robust and secure.



## Structure, governance and management

Scleroderma & Raynaud's UK (SRUK) is a Charitable Incorporated Organisation, registered charity number: 1161828.

SRUK is governed by its Constitution.

### The principal objects of the charity:

- To relieve persons suffering from Scleroderma and Raynaud's (systemic sclerosis), including the provision of financial support for such persons and their families in need;
- To advance the education and awareness of the public and health professionals in all aspects of Scleroderma and Raynaud's, including the provision and production of educational literature on these disorders; and
- To provide financial support for research into the cause, treatment, care and prevention of both Scleroderma and Raynaud's and the dissemination of the results of such research for the public benefit.

## Method of appointment or election of trustees

The management of the charity and the group is the responsibility of the Trustees who are elected and co-opted under the terms of the SRUK Constitution, registered with the Charity Commission on 26 May 2015.

## Merger

The merger between the RSA and SS to form SRUK occurred during the previous financial year (2015-16). The Charity Commission approved the formation of the new CIO named "Scleroderma & Raynaud's UK" in May 2015. Following this all staff and assets were transferred from the RSA and SS into SRUK.

Since SRUK launched, both the RSA and SS continue to exist as dormant inactive charities. This is to ensure that any funds that may be donated to either organisation can be received and then passed on to SRUK so we can continue our vital work.

## Organisational structure and decision making

The Trustees who served during the year are set out on page 43. The Trustees have been selected for their expertise and professional skills. They meet quarterly with the Chief Executive.

Peer reviewers are invited to assist with the review of grant applications made to SRUK and their recommendations are reported back to the trustees who then approve or reject grant applications on merit or on the funding available. In 2016/17 a Research sub-committee was established to bring further rigour to the process.

## Key management remuneration

SRUK is committed to a policy of equal pay and aims to ensure that salaries reflect the knowledge, skills, behaviours and capabilities required for satisfactory performance in each role whilst also demonstrating appropriate use of charitable donations. Salaries are benchmarked against the voluntary sector and where appropriate, other relevant job markets. Remuneration for key management personnel is handled in the same way as for all other staff.

## Public benefit

We have considered the Charity Commission's general guidance on public benefit when reviewing our aims and objectives and planning future activities. The Trustees always ensure that the activities undertaken are in line with the charitable objectives and aims of SRUK.

As highlighted in this report, some of our research grants are specifically targeted at trying to determine the cause of Scleroderma and Raynaud's, thereby helping the general population in finding better treatments in the future.

---

# Statement of trustees responsibilities and corporate governance

The Trustees are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and regulations.

---

Company law requires the Trustees to prepare financial statements for each financial year and the Trustees have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and the group and of the incoming resources and application of resources, including the income and expenditure, of the charitable group for that period.

## **In preparing these financial statements, the Trustees are required to:**

- Select the most suitable accounting policies and then apply them consistently
- Observe the methods and principles in the Charity SORP
- Make judgments and accounting estimates that are reasonable and prudent
- State whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements
- Prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable group will continue in business

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the charitable company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and the group and ensuring their proper application under charity law and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

## **In so far as each of the Trustees is aware:**

- There is no relevant audit information of which the charitable company's auditor are unaware
- The Trustees have each taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditors are aware of that information


The Trustees are responsible for the maintenance and integrity of the corporate and financial information included on the company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

haysmacintyre were appointed as statutory auditor by the Board on the 26th July 2017.

This report was approved by the Board of Trustees on 24th January 2018 including, in their capacity as company directors, the strategic report contained therein, and signed on their behalf by:



**Chris Coombe**  
Treasurer



---

# Independent auditor's report to the trustees of SRUK

---

We have audited the financial statements of Scleroderma and Raynaud's UK for the year ended 31 March 2017 which comprise the Consolidated Statement of Financial Activities, Charity Statement of Financial Activities, the Consolidated Balance Sheet, the Charity Balance Sheet, the Statement of Cash Flows and the related notes. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

This report is made solely to the charity's members, as a body, in accordance with Section 144 of the Charities Act 2011 and regulations made under section 154 of that Act. Our audit work has been undertaken so that we might state to the charity's Trustees those matters we are required to state to them in an Auditors' Report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity's Trustees as a body, for our audit work, for this report, or for the opinions we have formed.

## Respective responsibilities of trustees and auditor

As explained more fully in the Trustees' Responsibilities Statement set out on page 21, the trustees are responsible for the preparation of financial statements which give a true and fair view.

We have been appointed as auditor under section 144 of the Charities Act 2011 and report in accordance with regulations made under section 154 of that Act. Our responsibility is to audit and express an opinion on the financial statements in accordance with applicable law and International Standards on Auditing (UK and Ireland). Those standards require us to comply with the Auditing Practices Board's Ethical Standards for Auditors.

## Scope of the audit of the financial statements

A description of the scope of an audit of financial statements is provided on the Financial Reporting Council's website at [www.frc.org.uk/auditscopeukprivate](http://www.frc.org.uk/auditscopeukprivate).

## Opinion on financial statements

### In our opinion the financial statements:

- Give a true and fair view of the state of the group's and charity's affairs as at 31 March 2017, and of the net movement in funds, for the year then ended;
- Have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- Have been prepared in accordance with the requirements of the Charities Act 2011

## Matters on which we are required to report by exception

**We have nothing to report in respect of the following matters where the Charities Act 2011 requires us to report to you if, in our opinion:**

- The information given in the Trustees' Report is inconsistent in any material respect with the financial statements; or
- Sufficient accounting records have not been kept; or
- The financial statements are not in agreement with the accounting records and returns; or
- We have not received all the information and explanations we require for our audit

24th January 2018

### haysmacintyre

Statutory Auditor,  
10 Queen Street Place,  
London EC4R 1AG

haysmacintyre is eligible to act as an auditor in terms of section 1212 of the Companies Act 2006.



# Financial statements

## Consolidated statement of financial activities (Incorporating an income and expenditure account) For the year ended 31<sup>st</sup> March 2017

	Notes	General Funds 2017 (£)	Restricted Funds 2017 (£)	Total Funds 2017 (£)	Total Funds 2016 (£)
<b>Income from</b>					(Restated)
Donations and legacies	5	<b>523,746</b>	-	<b>523,746</b>	442,495
Other trading income	6	<b>69,436</b>	-	<b>69,436</b>	86,892
Investments	7	<b>6,103</b>	-	<b>6,103</b>	62,941
<b>Total income</b>		<b>599,285</b>	-	<b>599,285</b>	592,328
<b>Expenditure on</b>					
Raising funds	8	<b>166,888</b>	-	<b>166,888</b>	102,035
Charitable activities	9	<b>573,096</b>	<b>18,046</b>	<b>591,142</b>	649,390
<b>Total expenditure</b>		<b>739,984</b>	<b>18,046</b>	<b>758,030</b>	751,425
<b>Net expenditure before revaluations</b>		<b>(140,699)</b>	<b>(18,046)</b>	<b>(158,745)</b>	(159,097)
Gains and losses on revaluation of investment assets	16	<b>10,471</b>	-	<b>10,471</b>	(88,577)
<b>Net expenditure before other recognised gains and losses</b>		<b>(130,228)</b>	<b>(18,046)</b>	<b>(148,274)</b>	(247,674)
Gains and losses on the revaluations of fixed assets		-	-	-	(100,000)
<b>Net movement in funds</b>		<b>(130,228)</b>	<b>(18,046)</b>	<b>(148,274)</b>	(347,674)
<b>Total funds brought forward</b>		<b>1,270,488</b>	<b>18,046</b>	<b>1,288,534</b>	1,636,208
<b>Total funds carried forward</b>		<b>1,140,260</b>	-	<b>1,140,260</b>	1,288,534

The charity has no recognised gains or losses other than the results for the year as set out above.

All of the activities of the charity are classed as continuing.

From 01 November 2015 Raynaud's & Scleroderma Association Trust (RSA) and the Scleroderma Society (SS) merged and are reporting performance under Merger Accounting. The results for the year ended 31st March 2016 include RSA and SS as if they had always been merged.

The notes on pages 26-42 form part of these financial statements.



**Charity statement of financial activities (Incorporating an income and expenditure account)  
For the year ended 31<sup>st</sup> March 2017**

	Notes	General Funds 2017 (£)	Restricted Funds 2017 (£)	Total Funds 2017 (£)	Total Funds 2016 (£)
<b>Income from</b>					(Restated)
Donations and legacies	5	<b>523,746</b>	-	<b>523,746</b>	442,495
Other trading income	6	<b>13,211</b>	-	<b>13,211</b>	17,781
Investments	7	<b>6,103</b>	-	<b>6,103</b>	62,941
Other income		<b>10,903</b>	-	<b>10,903</b>	11,862
<b>Total income</b>		<b>553,963</b>	-	<b>553,963</b>	535,079
<b>Expenditure on</b>					
Raising funds	8	<b>119,429</b>	-	<b>119,429</b>	61,921
Charitable activities	9	<b>573,096</b>	<b>18,046</b>	<b>591,142</b>	631,520
<b>Total expenditure</b>		<b>692,525</b>	<b>18,046</b>	<b>710,571</b>	693,441
<b>Net expenditure before revaluations</b>		<b>(138,562)</b>	<b>(18,046)</b>	<b>(156,608)</b>	(158,362)
Gains and losses on revaluation of investment assets	16	<b>10,471</b>	-	<b>10,471</b>	(88,577)
<b>Net expenditure before other recognised gains and losses</b>		<b>(128,091)</b>	<b>(18,046)</b>	<b>(146,137)</b>	(246,939)
Gains and losses on revaluation of fixed assets		-	-	-	(100,000)
<b>Net movement in funds</b>		<b>(128,091)</b>	<b>(18,046)</b>	<b>(146,137)</b>	(346,939)
<b>Total funds brought forward</b>		<b>1,275,233</b>	<b>18,046</b>	<b>1,293,279</b>	1,640,218
<b>Total funds carried forward</b>		<b>1,147,142</b>	-	<b>1,147,142</b>	1,293,279

The charity has no recognised gains or losses other than the results for the year as set out above.

All of the activities of the charity are classed as continuing.

From 01 November 2015 Raynaud's & Scleroderma Association Trust (RSA) and the Scleroderma Society (SS) merged and are reporting performance under Merger Accounting. The results for the year ended 31st March 2016 include RSA and SS as if they had always been merged.

The notes on pages 26 to 42 form part of these financial statements.

**Consolidated and charity balance sheet  
As at 31<sup>st</sup> March 2017**

	Notes	Group 2017 (£)	Group 2016 (Restated) (£)	Charity 2017 (£)	Charity 2016 (Restated) (£)
<b>Fixed assets</b>					
Tangible assets	15	<b>200,800</b>	201,137	<b>200,695</b>	200,927
Investments	16	<b>512,710</b>	628	<b>512,710</b>	628
		<b>713,510</b>	201,765	<b>713,405</b>	201,555
<b>Current assets</b>					
Stock	18	<b>7,238</b>	5,532	-	-
Investments	17	-	1,443,052	-	1,443,052
Debtors: amounts falling due within one year	20	<b>144,230</b>	7,378	<b>205,367</b>	57,670
Cash at bank and in hand		<b>1,049,996</b>	380,487	<b>998,438</b>	331,857
		<b>1,201,464</b>	1,836,449	<b>1,203,805</b>	1,832,579
<b>Creditors: amounts falling due within one year</b>	21	<b>(774,714)</b>	(749,680)	<b>(770,068)</b>	(740,855)
<b>Net current assets</b>		<b>426,750</b>	1,086,769	<b>433,737</b>	1,091,724
<b>Total assets less current liabilities</b>		<b>1,140,260</b>	1,288,534	<b>1,147,142</b>	1,293,279
<b>Net assets</b>		<b>1,140,260</b>	1,288,534	<b>1,147,142</b>	1,293,279
<b>Capital and reserves</b>					
Restricted funds	22	-	18,046	-	18,046
Unrestricted funds	23	<b>1,140,260</b>	1,270,488	<b>1,147,142</b>	1,275,233
<b>Total funds</b>		<b>1,140,260</b>	1,288,534	<b>1,147,142</b>	1,293,279

These financial statements were approved and authorised for issue by the board on 24th January 2018 and are signed on their behalf by:



**Chris Coombe**  
Treasurer

The notes on pages 26-42 form part of these financial statements.



## Notes to the financial statement For the year ended 31<sup>st</sup> March 2017

---

### 1. General information

Scleroderma & Raynaud's UK ('the charity') and its subsidiary (together "the group") support the research of Raynaud's and Scleroderma diseases and offer advice and support to individuals suffering from the conditions throughout the UK.

Scleroderma & Raynaud's UK is a public benefit entity having registered charity number 1161828 and was incorporated in England. The address of its registered office is Bride House, 18-20 Bride Lane, London, EC4Y 8EE.

### 2. Accounting policies

#### A) Basis of Preparation of Financial Statements

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (effective 1 January 2015 - Charities SORP (FRS102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Charities Act 2011.

SRUK meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

The statement of financial activities (SOFA) and balance sheet consolidate the financial statements of the charity and its subsidiary undertaking being RSA Trading Company Limited. The results of the subsidiary are consolidated on a line by line basis after the elimination of intra-group transactions, control has been obtained by the ownership of shares.

#### Merger Accounting

SRUK was created to enable the merger of Raynaud's & Scleroderma Association Trust (RSA) and the Scleroderma Society (SS). Deeds were entered into by both RSA and SS that transferred their assets and undertaking to SRUK with effect from 1st November 2015. The agreements were made on the basis of the two equals coming together to serve common beneficiaries and the trustees consider that the arrangement qualifies as a merger and merger accounting has been adopted in the production of the consolidated and charity financial statements.

The charity accounts represent RSA and SS as the new merged entity SRUK. The consolidated accounts additionally include RSA Trading Company Limited, a trading subsidiary of SRUK.

#### B) Going concern

The Trustees continue to monitor the performance of the charity against budgets and forecasts for the foreseeable future in the difficult economic climate. Given the net current asset position at the year-end, the Trustees consider it appropriate to prepare the financial statements on the going concern basis.

#### C) Fund Accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the charity and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the charity for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

## **D) Income**

All income is recognised once the charity has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably. For legacies, entitlement is taken as the earlier of the date on which either: the charity is aware that probate has been granted, the estate has been finalised and notification has been made by the executor(s) to the Trust that a distribution will be made, or when a distribution is received from the estate. Receipt of a legacy, in whole or in part, is only considered probable when the amount can be measured reliably and the charity has been notified of the executor's intention to make a distribution. Where legacies have been notified to the charity, or the charity is aware of the granting of probate, and the criteria for income recognition have not been met, then the legacy is treated as a contingent asset and disclosed if material.

Donated services or facilities are recognised when the charity has control over the item, any conditions associated with the donated item have been met, the receipt of economic benefit from the use of the charity of the item is probable and that economic benefit can be measured reliably. In accordance with the Charities SORP (FRS 102), the general volunteer time of the friends is not recognised and refer to the Trustees' Report for more information about their contribution.

On receipt, donated professional services and donated facilities are recognised on the basis of the value of the gift to the charity which is the amount the charity would have been willing to pay to obtain services or facilities of equivalent economic benefit on the open market; a corresponding amount is then recognised in expenditure in the period of receipt.

Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Income tax recoverable in relation to investment income is recognised at the time the investment income is receivable.

## **E) Expenditure**

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably.

Expenditure is classified under the principal categories of charitable and other expenditure rather than the type of expense, in order to provide more useful information to users of the accounts.

Cost of raising funds are those incurred in seeking voluntary contributions, and those incurred in trading activities that raise funds but do not include the costs of disseminating information in support of the charitable activities.

Charitable activities comprise direct expenditure including direct staff costs attributable to the activity.

Support costs are those costs incurred directly in support of expenditure on the objects of the charity and include project management.

Governance costs are those incurred in connection with the management of SRUK's assets, organisational administration and compliance with constitutional and statutory requirements.

Support and Governance costs are allocated on the basis of time spent on each activity.

SRUK has a new grants policy in which grants are accounted for fully in the year they are awarded in accordance with Charities SORP (FRS102) requirements. They are therefore treated as liabilities in the accounts in the year they are awarded.



## **F) Tangible Fixed Assets**

All assets costing more than £500 are capitalised.

Tangible fixed assets are carried at cost or valuation, net of depreciation and any provision for impairment. Depreciation is not charged on freehold land. Depreciation is provided at rates calculated to write off the cost or valuation of fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

### **Office equipment**

20% straight line.

## **G) Revaluation of tangible fixed assets**

The charity has adopted the cost model whereby items of property, plant and equipment are measured at cost less any accumulated depreciation and any accumulated impairment losses.

## **H) Investments**

Fixed asset investments and current asset investments are a form of financial instrument and are initially recognised at their transaction cost and subsequently measured at fair value at the Balance Sheet date, unless fair value cannot be measured reliably in which case it is measured at cost less impairment. Investment gains and losses, whether realised or unrealised, are combined and shown in the heading 'Gains/(losses) on investments' in the Statement of Financial Activities.

### **Subsidiary undertakings**

Investments in subsidiaries are valued at cost less provision for impairment.

## **I) Interest receivable**

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the charity; this is normally upon notification of the interest paid or payable by the Bank.

## **J) Stocks**

Stocks are valued at the lower of cost and net realisable value after making due allowance for obsolete and slow-moving stocks. Cost includes all direct costs and an appropriate proportion of fixed and variable overheads.

## **K) Debtors**

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

## **L) Cash and cash equivalents**

Cash at bank and in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

## **M) Liabilities and provisions**

Liabilities are recognised when there is an obligation at the Balance Sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably. Liabilities are recognised at the amount that the charity anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide. Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised within interest payable and similar charges.

## **N) Financial Instruments**

The charity only enters into basic financial instruments transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties, loans to related parties and investments in non-puttable ordinary shares.

Debt instruments (other than those wholly repayable or receivable within one year), including loans and other accounts receivable and payable, are initially measured at present value of the future cash flows and subsequently at amortised cost using the effective interest method. Debt instruments that are payable or receivable within one year, typically trade payables or receivables, are measured, initially and subsequently, at the undiscounted amount of the cash or other consideration expected to be paid or received. However if the arrangements of a short-term instrument constitute a financing transaction, like the payment of a trade debt deferred beyond normal business terms or financed at a rate of interest that is not a market rate or in case of an out-right short-term loan not at market rate, the financial asset or liability is measured, initially, at the present value of the future cash flow discounted at a market rate of interest for a similar debt instrument and subsequently at amortised cost.

Financial assets that are measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in the profit and loss account.

For financial assets measured at amortised cost, the impairment loss is measured as the difference between an asset's carrying amount and the present value of estimated cash flows discounted at the asset's original effective interest rate. If a financial asset has a variable interest rate, the discount rate for measuring any impairment loss is the current effective interest rate determined under the contract.

For financial assets measured at cost less impairment, the impairment loss is measured as the difference between an asset's carrying amount and best estimate, which is an approximation of the amount that the charity would receive for the asset if it were to be sold at the balance sheet date.

Financial assets and liabilities are offset and the net amount reported in the Balance Sheet when there is an enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

## **O) Taxation**

The charity is exempt from tax on its charitable activities.

## **P) Termination benefits**

Settlement agreements are recognised in the period they are incurred.



### 3. Judgements in applying accounting policies and key sources of estimation uncertainty

Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

#### Critical accounting estimates and assumptions

The charity makes estimates and assumptions concerning the future. The resulting accounting estimates and assumptions will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below.

#### Critical areas of judgement

##### I) Useful economic lives of tangible assets

The annual depreciation charge for tangible assets is sensitive to changes in the estimated useful economic lives and residual values of the assets. The useful economic lives and residual values are re-assessed annually. They are amended when necessary to reflect current estimates, based on technological advancement, future investments, economic utilisation and the physical condition of the assets. See note 15 for the carrying amount of the tangible fixed assets and note 2(F) for the useful economic lives for each class of assets.

##### II) Impairment of fixed assets

At regular intervals, and at least annually, management review the carrying value of tangible fixed assets to determine whether this fairly represents the recoverable amount from their use. The carrying value is compared to the recoverable amount, defined as the higher of:

- Value in use is calculated from expected earnings streams or savings from continued employment of the asset
- Realisable value on a disposal

##### III) Accrued grants payable

Using the accruals basis of accounting, grants payable are matched to the period or are reported when the expense occurs, not when the cash is paid.

### 4. Net expenditure for the year

Net expenditure for the year is stated after charging

	Group		Charity	
	2017 (£)	2016 (£)	2017 (£)	2016 (£)
Depreciation on owned assets	337	6,206	232	6,101
Auditors' remuneration	8,100	13,943	8,100	13,268
Auditors' remuneration (prior year)	12,050	-	12,050	-

## 5. Donations & legacies

Group & Charity	Unrestricted Funds 2017 (£)	Restricted Funds 2017 (£)	Total Funds 2017 (£)	Total Funds 2016 (£)
Donation	<b>245,952</b>	-	<b>245,952</b>	266,992
Legacies	<b>277,794</b>	-	<b>277,794</b>	151,721
Grants	-	-	-	23,782
	<b>523,746</b>	-	<b>523,746</b>	442,495

## 6. Other trading income

Group	Unrestricted Funds 2017 (£)	Restricted Funds 2017 (£)	Total Funds 2017 (£)	Total Funds 2016 (£)
Trading income	<b>56,225</b>	-	<b>56,225</b>	72,019
Membership income	<b>11,111</b>	-	<b>11,111</b>	12,552
Conference income	<b>2,100</b>	-	<b>2,100</b>	2,321
	<b>69,436</b>	-	<b>69,436</b>	86,892

Charity	Unrestricted Funds 2017 (£)	Restricted Funds 2017 (£)	Total Funds 2017 (£)	Total Funds 2016 (£)
Trading income	-	-	-	2,908
Membership income	<b>11,111</b>	-	<b>11,111</b>	12,552
Conference income	<b>2,100</b>	-	<b>2,100</b>	2,321
	<b>13,211</b>	-	<b>13,211</b>	17,781

## 7. Investment income

Group & Charity	Unrestricted Funds 2017 (£)	Restricted Funds 2017 (£)	Total Funds 2017 (£)	Total Funds 2016 (£)
Dividend income	<b>2,238</b>	-	<b>2,238</b>	62,536
Bank interest income	<b>3,865</b>	-	<b>3,865</b>	405
	<b>6,103</b>	-	<b>6,103</b>	62,941



## 8. Raising funds

Group	Total 2017 (£)	Total 2016 (£)
Expenditure on generating donations, legacies and memberships	<b>15,534</b>	16,705
Expenditure on goods sold and costs	<b>47,459</b>	41,289
Fundraising staff costs	<b>60,194</b>	44,041
Support costs (Note 11)	<b>37,712</b>	-
Governance costs (Note 12)	<b>5,989</b>	-
	<b>166,888</b>	102,035

Charity	Total 2017 (£)	Total 2016 (£)
Expenditure on generating donations, legacies and memberships	<b>15,534</b>	16,705
Expenditure on goods sold and costs	-	1,175
Fundraising staff costs	<b>60,194</b>	44,041
Support costs (Note 11)	<b>37,712</b>	-
Governance costs (Note 12)	<b>5,989</b>	-
	<b>119,429</b>	61,921

## 9. Charitable activities

Group	Unrestricted Funds (£)	Restricted Funds (£)	Total 2017 (£)	Total 2016 (£)
Direct costs (Note 10)	<b>408,698</b>	<b>18,046</b>	<b>426,744</b>	223,582
Support costs (Note 11)	<b>141,868</b>	-	<b>141,868</b>	397,411
Governance costs (Note 12)	<b>22,530</b>	-	<b>22,530</b>	28,397
	<b>573,096</b>	<b>18,046</b>	<b>591,142</b>	649,390

Charity	Unrestricted Funds (£)	Restricted Funds (£)	Total 2017 (£)	Total 2016 (£)
Direct costs (Note 10)	<b>408,698</b>	<b>18,046</b>	<b>426,744</b>	223,477
Support costs (Note 11)	<b>141,868</b>	-	<b>141,868</b>	380,320
Governance costs (Note 12)	<b>22,530</b>	-	<b>22,530</b>	27,722
	<b>573,096</b>	<b>18,046</b>	<b>591,142</b>	631,520

## 10. Direct costs

Group	Unrestricted Funds 2017 (£)	Restricted Funds 2017 (£)	Total Funds 2017 (£)	Total Funds 2016 (£)
Grants payable	134,694	10,546	145,240	72,253
Staff costs	185,324	-	185,324	32,382
Admin expenses	7,710	-	7,710	87,452
Other direct costs	80,970	7,500	88,470	31,495
	<b>408,698</b>	<b>18,046</b>	<b>426,744</b>	223,582

Charity	Unrestricted Funds 2017 (£)	Restricted Funds 2017 (£)	Total Funds 2017 (£)	Total Funds 2016 (£)
Grants payable	134,694	10,546	145,240	72,253
Staff costs	185,324	-	185,324	32,382
Admin expenses	7,710	-	7,710	87,452
Other direct costs	80,970	7,500	88,470	31,390
	<b>408,698</b>	<b>18,046</b>	<b>426,744</b>	223,477

## Grants

Group & Charity	2017 (£)	2016 (£)
<b>Grant commitments are as follows</b>		
Grant commitments at 1 April	660,335	1,186,607
Awards made during year	145,240	261,718
Payments made during the year	(115,825)	(598,525)
Grants retracted	-	(189,465)
Grant commitments at 31 March	<b>689,750</b>	660,335

## Analysis of grants payable

	Group		Charity	
	2017 (£)	2016 (£)	2017 (£)	2016 (£)
University College London	80,000	36,873	80,000	36,873
University of Manchester	-	98,876	-	98,876
Royal Free Hospital	-	112,630	-	112,630
Royal National Hospital for Rheumatic Diseases	45,000	-	45,000	-
Alder Hay	20,000	-	20,000	-
Calcinosis	-	3,000	-	3,000
Grants to individuals	240	1,349	240	1,349
Other	-	8,990	-	8,990
	<b>145,240</b>	261,718	<b>145,240</b>	261,718

Of the total grants payable £145,000 relates to grants payable to institutions (2016: £260,369)



## 11. Support costs

Group	Total 2017 (£)	Total 2016 (£)
Staff costs	<b>32,250</b>	135,815
Other staff costs	<b>12,910</b>	6,532
Facilities	<b>17,600</b>	3,188
Finance & Legal	<b>33,344</b>	86,344
Office costs	<b>26,444</b>	16,219
Merger	<b>57,032</b>	149,313
	<b>179,580</b>	397,411

Charity	Total 2017 (£)	Total 2016 (£)
Staff costs	<b>32,250</b>	135,815
Other staff costs	<b>12,910</b>	5,702
Facilities	<b>17,600</b>	3,188
Finance & Legal	<b>33,344</b>	81,618
Office costs	<b>26,444</b>	4,684
Merger	<b>57,032</b>	149,313
	<b>179,580</b>	380,320

## 12. Governance costs

Group	Total 2017 (£)	Total 2016 (£)
Staff costs	<b>6,223</b>	4,318
Audit	<b>20,150</b>	13,943
Other costs	<b>2,146</b>	10,136
	<b>28,519</b>	28,397

Charity	Total 2017 (£)	Total 2016 (£)
Staff costs	<b>6,223</b>	4,318
Audit	<b>20,150</b>	13,268
Other costs	<b>2,146</b>	10,136
	<b>28,519</b>	27,722

### 13. Staff costs

Staff costs were as follows:

	Group		Charity	
	2017 (£)	2016 (£)	2017 (£)	2016 (£)
Wages and salaries	<b>249,788</b>	203,765	<b>238,885</b>	203,765
Social security costs	<b>23,299</b>	12,791	<b>23,299</b>	12,791
	<b>273,087</b>	216,556	<b>262,184</b>	216,556

The average number of employees during the year was as follows:

	2017 (No.)	2016 (No.)
Staff	<b>11</b>	10

Employees receiving remuneration amounting to more than £60,000 were as follows:

	2017 (No.)	2016 (No.)
Remuneration £70,000 - £79,999	<b>1</b>	1

During the year redundancy was paid of £18,363 (2016: £22,613).

The key management personnel of the charity comprise the trustees and the senior management team as listed on page 1. The total amount of employee benefits (including employer pension contributions) received by key management personnel for their services to SRUK was £149,296 (2016: £151,140).

In 2015-16 total staff costs came to £263,542, of which £216,556 was included in staff costs and the remaining £46,986 was allocated to other expense groups. In 2016-17 these allocations have been reviewed and amended with all staff related costs being included solely within staff costs, the total of which amounts to £273,087.

### 14. Trustees

None of the trustees (or any person connected with them) received any remuneration during the year, and total expenses reimbursed to trustees was £1,997 relating to four trustees for travelling and other expenses (2016 - £2,913).



## 15. Fixed assets

Group	Freehold land and buildings (£)	Furniture and equipment (£)	Fixtures and fittings (£)	Total (£)
<b>Cost</b>				
At 1 April 2016	200,000	1,684	29,567	<b>231,251</b>
Disposal	-	-	(29,567)	<b>(29,567)</b>
At 31 March 2017	200,000	1,684	-	<b>201,684</b>
<b>Depreciation</b>				
At 1 April 2016	-	547	29,567	<b>30,114</b>
Depreciation charge	-	337	-	<b>337</b>
Disposal	-	-	(29,567)	<b>(29,567)</b>
At 31 March 2017	-	884	-	<b>884</b>
<b>Net Book Value</b>				
At 31 March 2016	200,000	1,137	-	<b>201,137</b>
At 31 March 2017	200,000	800	-	<b>200,800</b>
<b>Charity</b>				
	Freehold land and buildings (£)	Furniture and equipment (£)	Fixtures and fittings (£)	Total (£)
<b>Cost</b>				
At 1 April 2016	200,000	1,159	29,567	<b>230,726</b>
Disposal	-	-	(29,567)	<b>(29,567)</b>
At 31 March 2017	200,000	1,159	-	<b>201,159</b>
<b>Depreciation</b>				
At 1 April 2016	-	232	29,567	<b>29,799</b>
Depreciation charge	-	232	-	<b>232</b>
Disposal	-	-	(29,567)	<b>(29,567)</b>
At 31 March 2017	-	464	-	<b>464</b>
<b>Net Book Value</b>				
At 31 March 2016	200,000	927	-	<b>200,927</b>
At 31 March 2017	200,000	695	-	<b>200,695</b>

A range of valuations were obtained for freehold land and buildings.

Fixtures and Fittings relating to the property in Alsager have been retired due to the closure of the office.

## 16. Fixed asset investments

Group & Charity	2017 Total (£)
<b>Quoted Investments</b>	
Market value of quoted investments at 1 April 2016	628
Additions	445,722
Disposal proceeds	-
Net Investment Gain	10,471
Market value of quoted investments at 31 March 2017	456,821
Cash on deposit	55,889
Market value at 31 March 2017	512,710
Historic cost at 31 March 2017	502,239
Accumulated unrealised gain	10,471
<b>Historic Cost Gains</b>	
Net investment gain	10,471
Movement on unrealised gain	(10,471)
Realised gains based on historic cost	-

All the fixed asset investments are held in the UK.  
Quoted investments have been valued at market value at the balance sheet date.

UK Quoted investments are represented by	2017	2016
Cash	55,889	-
Equity	136,702	628
Fixed interest	121,064	-
Alternatives	68,839	-
Overseas	130,216	-
Total	512,710	628

## 17. Current asset investments

	Group		Charity	
	2017 (£)	2016 (£)	2017 (£)	2016 (£)
Unlisted securities	-	1,443,052	-	1,443,052

## 18. Stock

	Group		Charity	
	2017 (£)	2016 (£)	2017 (£)	2016 (£)
Stock	7,238	5,532	-	-



## 19. Financial instruments

	Group		Charity	
	2017 (£)	2016 (£)	2017 (£)	2016 (£)
Financial instruments measured at amortised cost	<b>1,183,446</b>	387,815	<b>1,129,414</b>	337,956
Financial liabilities measured at amortised cost	<b>762,108</b>	739,525	<b>757,163</b>	730,821

Financial assets measured at amortised cost comprise bank and cash, trade debtors, other debtors and accrued income.

Financial liabilities measured at amortised cost comprise trade creditors, other creditors, accruals and grant commitments.

## 20. Debtors

	Group		Charity	
	2017 (£)	2016 (£)	2017 (£)	2016 (£)
<b>Due within one year</b>				
Trade debtors	<b>2,592</b>	4,461	<b>117</b>	3,183
Amounts owed by group entities	-	-	<b>63,621</b>	51,570
Accrued income	<b>127,587</b>	-	<b>127,587</b>	-
Other debtors	<b>3,271</b>	2,917	<b>3,271</b>	2,917
Prepayments	<b>10,780</b>	-	<b>10,771</b>	-
	<b>144,230</b>	7,378	<b>205,367</b>	57,670

## 21. Creditors

	Group		Charity	
	2017 (£)	2016 (£)	2017 (£)	2016 (£)
Trade creditors	<b>47,721</b>	41,981	<b>46,551</b>	34,902
Other creditors	<b>179</b>	3,754	<b>179</b>	3,754
Deferred income	<b>3,791</b>	7,872	<b>3,791</b>	7,872
Taxes and social security	<b>8,815</b>	2,237	<b>9,114</b>	2,166
Accruals	<b>24,458</b>	33,501	<b>20,683</b>	31,826
Grant commitments	<b>689,750</b>	660,335	<b>689,750</b>	660,335
	<b>774,714</b>	749,680	<b>770,068</b>	740,855

### Deferred income

	Group (£)	Charity (£)
Opening balance	7,872	7,872
Resources released in the year	(7,872)	(7,872)
Resources deferred in the year	3,791	3,791
Closing balance	<b>3,791</b>	<b>3,791</b>

Deferred income relates to deferred membership subscriptions.

## 22. Restricted funds

Group & Charity - Current Year	Funds brought forward	Income	Expenditure including gains and losses	Funds carried forward
	(£)	(£)	(£)	(£)
Brian Norris appeal	10,546	-	(10,546)	-
Actelion	7,500	-	(7,500)	-
	<b>18,046</b>	<b>-</b>	<b>(18,046)</b>	<b>-</b>

Actelion's grant of £7,500 was used to produce a Digital Ulcer publication educating patients on the signs and symptoms, causes and treatment pathway, whilst empowering them to care for digital ulcers at home through expert self-management information.

The Brian Norris donation of £10,546 was used to create patient education videos. These videos were produced in partnership with specialists from across the UK providing accessible expert information on Scleroderma and Raynaud's.

Group & Charity - Prior year	Funds brought forward	Income	Expenditure including gains and losses	Funds carried forward
	(£)	(£)	(£)	(£)
BAD	274	-	(274)	-
Marjorie Ingram legacy	73,768	-	(73,768)	-
Medical equipment appeal	100	35	(135)	-
Research	245	160	(405)	-
Brian Norris appeal	-	25,929	(15,383)	10,546
Actelion	-	11,000	(3,500)	7,500
FESCA	-	10,052	(10,052)	-
	<b>74,387</b>	<b>47,176</b>	<b>(103,517)</b>	<b>18,046</b>

The British Association of Dermatologists ("BAD") grant was to help towards the production of a series of online patient information videos.

Under the terms of the legacy bequeathed by Marjorie Ingram, the amounts received are to be used for medical research.

On 1 November 2015, the restricted fund was transferred to Scleroderma & Raynaud's UK.

SS received a donation from The Brian Norris Charity Appeal of the value £25,929 to fund an ultra sound machine for the PITU unit at the Royal Free hospital, providing patients with a choice of treatment and a Family Day to inform, educate and empower families to better manage their child's condition.

Actelion provided a grant of £11,000 (£9,500 to RSA and £1,500 to SS) of which SS spent the full £1,500 on featuring Scleroderma in the Rare Disease Day pull out within the Guardian newspaper. The RSA spent £2,000 of the Actelion grant towards the annual conference as requested by Actelion and the remaining £7,500 has been ring-fenced for the following year to produce a comprehensive publication discussing Digital Ulcers - this publication will be patient focussed to educate and empower those affected by digital ulcers.

FESCA provided a grant of £10,052 in order to project manage the World Scleroderma Day (WSD) campaign for Europe. This grant was spent on the development of a dedicated WSD website to unite Scleroderma organisations across Europe. The grant was also spent on core costs to enable Scleroderma representatives to travel to Brussels and discuss Scleroderma at European Parliament.



## 23. Unrestricted funds

Group	Funds brought forward	Income	Expenditure including gains and losses	Funds carried forward
	(£)	(£)	(£)	(£)
	£	£	£	£
General	1,112,122	599,285	(729,513)	981,894
Revaluation	158,366	-	-	158,366
	<b>1,270,488</b>	<b>599,285</b>	<b>(729,513)</b>	<b>1,140,260</b>

Charity	Funds brought forward	Income	Expenditure including gains and losses	Funds carried forward
	(£)	(£)	(£)	(£)
	£	£	£	£
General	1,116,867	553,963	(682,054)	988,776
Revaluation	158,366	-	-	158,366
	<b>1,275,233</b>	<b>553,963</b>	<b>(682,054)</b>	<b>1,147,142</b>

The development fund comprises unrestricted funds which the trustees have designated for the development and growth of the organisation. The balance of the fund was transferred to unrestricted funds during 2016.

## 24. Analysis of net assets

Group	Unrestricted	Designated	Restricted	Total
	(£)	(£)	(£)	(£)
Tangible fixed assets	200,800	-	-	<b>200,800</b>
Investments	512,710	-	-	<b>512,710</b>
Current assets	1,201,464	-	-	<b>1,201,464</b>
Current liabilities	(774,714)	-	-	<b>(774,714)</b>
	<b>1,140,260</b>	<b>-</b>	<b>-</b>	<b>1,140,260</b>

Charity	Unrestricted	Designated	Restricted	Total
	(£)	(£)	(£)	(£)
Tangible fixed assets	200,695	-	-	<b>200,695</b>
Investments	512,710	-	-	<b>512,710</b>
Current assets	1,203,805	-	-	<b>1,203,805</b>
Current liabilities	(770,068)	-	-	<b>(770,068)</b>
	<b>1,147,142</b>	<b>-</b>	<b>-</b>	<b>1,147,142</b>

## 25. Going concern

Financial statements have been prepared on the going concern basis, no material uncertainties exist over the going concern assumption.

## 26. Related parties

During the year staff recharges of £10,903 (2016 - £11,952) were made to RSA Trading Company Limited, as at the 31 March 2017 SRUK are due £47,597 (£51,570 - 2016) from RSA Trading Company Limited.

All transactions were carried out at arm's length.

## 27. Principal subsidiaries

Company Name	Country	Percentage	Description
RSA Trading Company Limited	United Kingdom	100%	Sale of products to help with the medical conditions of Raynaud's and Scleroderma

The subsidiary was registered in England and Wales with registered number 07869668.

Financial review	2017 (£)	2016 (15 months) (£)
Net assets	<b>(6,877)</b>	(5,484)
Income	<b>56,225</b>	94,692
Expenditure	<b>(57,617)</b>	(98,315)
Loss	<b>(1,392)</b>	(3,623)

These are for the 12 months ending 31 March 2017.

## 28. Operating leases

Operating Leases - Buildings	2017 (£)	2016 (15 months) (£)
Amounts due		
< 1 year	<b>8,064</b>	8,064
2-5 years	<b>30,240</b>	5,376
>5 years	-	-
Total	<b>38,304</b>	13,440



## 29. Prior year adjustment

In the current year the Trustees elected to change the accounting policy for grant expenditure to recognise the full value of the grant as a liability at the point of award, rather than as invoices from awardees were received. As a result of this change in policy the prior year figures have been restated. The effect of this change is set out below.

<b>Group</b>	<b>2016 (£)</b>	<b>2015 (£)</b>
<b>Financial review</b>		
Net assets brought forward at 1 April as previously stated	1,797,586	2,822,815
Less: Grants awarded under revised policy	(509,052)	(1,186,607)
Net assets brought forward at 1 April as restated	1,288,534	1,636,208
<b>Net movement in funds for the year ended 31 March 2016</b>	(1,025,229)	
Add: Grant expenditure previously recognised	749,809	
Less: Grant expenditure awarded	(72,254)	
Net movement in funds for the year ended 31 March 2016 as restated	(347,674)	
<b>Charity</b>		
<b>Financial review</b>		
Net assets brought forward at 1 April as previously stated	1,802,331	2,826,825
Less: Grants awarded under revised policy	(509,052)	(1,186,607)
Net assets brought forward at 1 April as restated	1,293,279	1,640,218
<b>Net movement in funds for the year ended 31 March 2016</b>	(1,024,494)	
Add: Grant expenditure previously recognised	749,809	
Less: Grant expenditure awarded	(72,254)	
Net movement in funds for the year ended 31 March 2016 as restated	(346,939)	

## Who we are

### Trustees

Prof. Jeremy Pearson - Chair  
Helena Rozga - Vice-chair  
Christopher Coombe - Treasurer  
Prof. David GI Scott  
Jo Kaddish (Resigned 4th September 2016)  
Kenneth Hicks  
Susan Hoare

### Chief Executive Officer

Sue Farrington

### Key Management Personnel

Sue Farrington  
David Kesel  
Amy Baker  
Martha Wildemann

### Principal Bankers

NatWest Bank,  
1 Upper Market Square, Hanley,  
Stoke-on-Trent ST11NS

CAF Bank Limited,  
25 Kings Hill Avenue,  
Kings Hill, West Malling,  
Kent ME19 4JQ

### Solicitors

DLA Piper,  
3 Noble Street,  
London EC2V 7EE

### Auditors

haysmacintyre,  
10 Queen Street Place,  
London EC4R 1AG



**Principal Address  
and Registered Office**

---

Bride House  
18-20 Bride Lane  
London EC4Y 5EE